AP Biosciences

AP Biosciences Interest Coverage

The Interest Coverage Ratio of AP Biosciences (6945.TWO) as of Nov 17, 2026 is -27.22. In the previous year, Interest Coverage Ratio was -43.46 — a change of -37.37% (higher).

Interest Coverage

-27.22

YoY

-37.37%

Last updated:

Interest Coverage Ratio of AP Biosciences is 2024 -27.22 . Interest Coverage Ratio of AP Biosciences was 2023 -43.46 . It decreases by -37.37% higher compared to the previous year.

The AP Biosciences Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2020
12.44 TWD
Jan 1, 2021
-169.90 TWD
Jan 1, 2022
-32.58 TWD
Jan 1, 2023
-43.46 TWD
Jan 1, 2024
-27.22 TWD
The AP Biosciences Interest Coverage history
YEARInterest CoverageYoY
-27.22-37.37%
-43.46+33.38%
-32.58-80.82%
-169.90-1,465.46%
12.44—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AP Biosciences Stock analysis

What does AP Biosciences do? AP Biosciences Inc generates revenue through the development and commercialization of protein and antibody drugs. The company focuses on early-stage drug candidates and preclinical trials, utilizing its technology platforms to create monoclonal and bispecific antibody drugs. Key products include IBI302, OmniMab, AP505, T-cube, and AP203, which target specific disease mechanisms and therapeutic areas. The primary buyers are pharmaceutical companies seeking to expand their drug pipelines through partnerships and licensing agreements. The firm's technology platforms, such as OmniMab fully human antibody library and T-cube, enable the development of novel bispecific antibodies. These platforms support the creation of drugs like AP505-PD-L1 x VEGF bispecific antibody and AP203-PD-L1 x CD137 fully human bispecific antibody, which are designed for specific therapeutic targets. The company's research and development efforts target diseases with high unmet medical needs, attracting interest from potential collaborators in the biopharmaceutical sector. AP Biosciences Inc's business model relies on advancing its pipeline of drug candidates through preclinical and clinical stages, with the goal of securing partnerships or licensing deals with larger pharmaceutical firms. The company's focus on bispecific antibody technology and its proprietary platforms positions it to generate revenue from milestone payments and royalties upon successful development and commercialization of its drug candidates. AP Biosciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AP Biosciences stock

Interest Coverage Ratio of AP Biosciences is -27.22 in 2024.

Interest Coverage Ratio of AP Biosciences changed from -43.46 to -27.22, representing a -37.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio AP Biosciences since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's AP Biosciences with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — AP Biosciences

All Key Metrics — AP Biosciences